Inborn Gene or Chromosome Alterations Pipeline Research Report 2023: Analysis of Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Inborn Gene or Chromosome Alterations Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" report has been added to * ResearchAndMarkets.com's* offering.
Inborn Gene or Chromosome Alterations Pipeline Report provides comprehensive information about the Inborn Gene or Chromosome Alterations pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Genetic tests to detect monogenetic disorders (like Cystic Fibrosis, Haemochromatosis, Prothrombin Mutation etc), polygenetic disorders (like Asthma , Atherosclerosis, Diabetes, Hypertension, Osteoporosis, etc), chromosomal disorders (like Down's Syndrome, Edwards Syndrome etc), polymorphisms (like HLA-Typing etc).
*Scope*
· Extensive coverage of the Inborn Gene or Chromosome Alterations under development
· The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
· The report reviews the major players involved in the development of Inborn Gene or Chromosome Alterations and list all their pipeline projects
· The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
· The report provides key clinical trial data of ongoing trials specific to pipeline products
· Recent developments in the segment / industry
*Reasons to Buy*
· Formulate significant competitor information, analysis, and insights to improve R&D strategies
· Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
· Identify and understand important and diverse types of Inborn Gene or Chromosome Alterations under development
· Develop market-entry and market expansion strategies
· Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
· In-depth analysis of the product's current stage of development, territory and estimated launch date
*Key Topics Covered:*
*1 Table of Contents*
1.1 List of Tables
1.2 List of Figures
*2 Introduction*
2.1 Inborn Gene or Chromosome Alterations Overview
*3 Products under Development*
3.1 Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development
3.2 Inborn Gene or Chromosome Alterations - Pipeline Products by Territory
3.3 Inborn Gene or Chromosome Alterations - Pipeline Products by Regulatory Path
3.4 Inborn Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date
3.5 Inborn Gene or Chromosome Alterations - Ongoing Clinical Trials
*4 Inborn Gene or Chromosome Alterations - Pipeline Products under Development by Companies*
4.1 Inborn Gene or Chromosome Alterations Companies - Pipeline Products by Stage of Development
4.2 Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development
*5 Inborn Gene or Chromosome Alterations Companies and Product Overview*
*6 Inborn Gene or Chromosome Alterations- Recent Developments*
*7 Appendix*
*A selection of companies mentioned in this report includes*
· Aarhus University
· AC-Gen Reading Life S.L.
· Alexion Pharmaceuticals Inc
· Amarantus Diagnostics Inc
· Arrayit Corp (Inactive)
· Augusta University
· AutoGenomics Inc
· Baylor College of Medicine
· Boston Children's Hospital
· CareDx Inc
· Children's Hospital of Philadelphia
· Cincinnati Children's Hospital Medical Center
· Columbia University
· Columbia University Fertility Center
· Daan Gene Co Ltd
· Decipher GenX, Inc.
· Duke University
· Epinex Diagnostics Inc
· Firalis SAS
· Fraunhofer Institute for Cell Therapy and Immunology
· Fred Hutchinson Cancer Research Center
· French National Institute of Health and Medical Research
· genedrive plc
· Genentech USA Inc
· Genomic Vision SA
· genomiQa Pty Ltd
· German Cancer Research Center
· German Institute of Human Nutrition
· Gilupi GmbH
· Helmholtz Center Munich German Research Center for Health and Environment GmbH
· Hummingbird Diagnostics GmbH
· Interleukin Genetics Inc (Inactive)
· Interpace Biosciences Inc
· Johns Hopkins University
· JS Genetics Inc
· LS CancerDiag Ltd
· Lucid Diagnostics Inc
· Massachusetts Eye and Ear Infirmary
· McGill University
· Medical Research Council
· Molecular Stethoscope Inc
· Nanosphere Inc (Inactive)
· National University of Singapore
· Nel ASA
· NewGene Ltd
· Oxford Biodynamics Plc
· Population Bio Inc
· Precipio Inc
· Predigen Inc
· Quest Diagnostics Inc
· Revvity Inc
· Sapien Biosciences
· Scipher Medicine Corp
· Seattle Children's Hospital
· Seegene Inc
· Sophia Genetics SA
· Strand Life Sciences Pvt Ltd
· SUNY Upstate Medical University
· Suzhou Basecare Medical Co Ltd
· TBG Diagnostics Ltd
· Tel Aviv University
· Transplant Genomics Inc
· University of California San Diego
· University of Central Florida
· University of Colorado
· University of Illinois at Chicago
· University of Michigan
· University of Pennsylvania
· University of Pittsburgh
· Vanderbilt University
· Vanessa Biotech
· Virginia Commonwealth University
· VitaPath Genetics, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/r0vljs
*About ResearchAndMarkets.com*
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900